平价医疗法案实施前后局部晚期宫颈癌指南依从性放化疗的趋势
基于美国国家癌症数据库2004至2016年37,772例局部晚期宫颈癌患者的分析显示,平价医疗法案实施后指南依从性放化疗比例从28%升至34%(P<0.001),2年生存率从62%升至69%(P<0.001);指南依从治疗者2年生存率76% vs 非依从者61%(P<0.001)。
要点
- 平价医疗法案实施后指南依从性放化疗比例由28%升至34%(P<0.001)。
- 指南依从治疗者2年生存率76% vs 非依从者61%,提高15%(P<0.001)。
- 联邦医疗保险(OR 0.91;95%CI 0.84-0.99)和非鳞状组织学与指南依从治疗几率降低相关。
核心结论
- 平价医疗法案的实施与局部晚期宫颈癌患者指南依从性放化疗及生存改善相关。
研究设计与样本
- 基于美国国家癌症数据库的回顾性分析,纳入2004至2016年接受放化疗的局部晚期宫颈癌患者(FIGO 2018 IB3-IVA期)共37,772例,其中平价医疗法案前16,169例、法案后21,673例。
主要发现
- 指南依从性放化疗比例法案前为28%,法案后为34%(P<0.001)。
- 指南依从治疗者2年生存率为76%,非依从者为61%,提高15%(P<0.001)。
- 法案后队列2年生存率为69%,法案前为62%(P<0.001)。
- 多变量分析中,联邦医疗保险较商业保险的OR为0.91(95%CI 0.84-0.99),腺癌较鳞癌的OR为0.83(95%CI 0.77-0.89),Charlson-Deyo评分增加均与接受指南依从治疗几率降低相关;T分期增加与接受指南依从性放化疗几率增高相关。
关键数值与推荐
- 指南依从性放化疗定义依据NCCN指南,包括:1)外照射放疗;2)近距离放疗;3)化疗;4)无根治性子宫切除术。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess trends in guideline-adherent chemoradiation therapy (GA-CRT) for locally advanced cervical cancer relative to Patient Protection and Affordable Care Act (ACA) implementation. METHODS: National Cancer Database patients treated with chemoradiation for locally advanced cervical cancer (FIGO 2018 Stage IB3-IVA) from 2004 to 2016 were included. GA-CRT was defined according to NCCN guidelines and included: 1) delivery of external beam radiation, 2) brachytherapy, and 3) chemotherapy, 4) no radical hysterectomy. Logistic regression was used to determine trends in GA-CRT relative to the ACA. Survival was also estimated using Kaplan-Meier analysis. RESULTS: 37,772 patients met inclusion criteria (Pre-ACA:16,169; Post-ACA:21,673). A total of 33,116 patients had squamous cell carcinoma and 4626 patients had other histologies. Forty-five percent of patients had lymph node-positive disease. A total of 14.6% of patients had Stage I disease, 41.8% had Stage II disease, 36.4% had Stage III disease, and 7.9% had Stage IVA disease. On multivariable analysis, medicare insurance (OR 0.91; 95%CI: 0.84-0.99 compared to commercial insurance), non-squamous histology (OR 0.83; 95%CI: 0.77-0.89 for adenocarcinoma) and increasing Charlson-Deyo score were associated with decreased odds of receiving GA care. Increasing T-stage was associated with greater receipt of GA-CRT. The percentage of the population that received guideline adherent care increased post-ACA (Pre-ACA 28%; Post-ACA 34%; p < 0.001). Adherence to treatment guidelines increased 2-year survival by 15% (GA 76%; Not GA 61%; p < 0.001). Increased 2-year survival was seen in the post-ACA cohort (Pre-ACA 62%; Post-ACA 69%; p < 0.001). CONCLUSIONS: Implementation of the ACA was associated with improved GA-CRT and survival in patients with locally advanced cervical cancer.
引用
- Thomas RJ, Provenzano D, Goyal S, et al. Trends in guideline-adherent chemoradiation therapy for locally advanced cervical cancer before and after the affordable care act. Gynecol Oncol. 2022. PMID: 35491268. doi:10.1016/j.ygyno.2022.04.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。